FDA gets sweeping power to destroy imports with minimal oversight

What it does

This bill expands the FDA's power to destroy imported goods that are refused entry into the U.S. Currently, the FDA can destroy certain refused drugs and devices; this bill extends that authority to any article (food, cosmetics, supplements, etc.) that the FDA Secretary determines presents a significant public health concern. It also makes it illegal to move or sell an article that the FDA has decided to destroy.

Why we flagged it

The bill's operative mechanism is a straightforward expansion of existing FDA destruction authority over refused imports. It is not deregulation, not a carve-out, and not a rider — it is a direct grant of new discretionary power to a federal agency.

What the text implies

• The bill does not define 'significant public health concern' — the FDA Secretary's determination is the sole standard, with no requirement to publish reasoning, consult stakeholders, or provide notice to affected importers before destruction.
• No appeal or administrative review process is established; importers have no statutory right to contest a destruction decision or recover losses.
• The 180-day implementation window and 90-day regulatory deadline create pressure for rapid rulemaking without full stakeholder input, potentially leaving the standard vague.
• Expansion to 'any article' (not just drugs/devices) may capture cosmetics, dietary supplements, food additives, and other categories with different regulatory histories and international trade implications.
• The bill requires consistency with international agreements but does not specify which agreements or how conflicts are resolved if the FDA's discretion conflicts with trade obligations.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens benefit from faster removal of genuinely hazardous imports (contaminated food, counterfeit medicines, unsafe products). However, the bill grants the FDA Secretary broad discretion to declare an article a public health concern with no defined standard, no mandatory notice to importers, no appeal process, and no requirement to publish findings — creating risk of arbitrary destruction and potential trade friction without transparency.

Named in the bill

FDA, Secretary of Health and Human Services, Commissioner of Food and Drugs, Federal Food, Drug, and Cosmetic Act, Section 801(a), Section 301

Where it stands

3 cosponsors: 3 Republicans.

• Nov 19, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Nov 19, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 2 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $3,245,000 in lobbying spend. A filing names 21 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Rick Scott, the sponsor, reported $69,750 in PAC receipts in the 2026 cycle.

• Altria Client Services LLC — $3,200,000 on 1 filing
• Southern Shrimp Alliance — $45,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.